Already many years ago in 1997 we knew that maternal plasma contains DNA from an ongoing pregnancy the form of cell-free fetal DNA(cffDNA). Rapid advances in molecular biology analysis techniques have led to the development of next‐generation sequencing (NGS), have given us the possibility to capture and analyze cffDNA. With a simple and safe blood draw, chromosomal disorders like trisomy 21(Down syndrome), trisomy 18 (Edwards syndrome)  and trisomy 13 (Patau syndrome), sex chromosome aneuploidies (SCA) as well as so called microdeletions can be detected with high accuracy (>99%) as early the 9th week of gestation. Apart from being an easy and noninvasive method, current data also reveal that NIPT is more accurate than conventional first-trimester screening (1).